CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

pectin

Botanicalexperimental

Pectin is a heteropolysaccharide, a structural polymer contained in the cell walls and middle lamellae of terrestrial plants. The principal chemical component of pectin is galacturonic acid which was isolated and described by Henri Braconnot in 1825. Commercially produced pectin is a white-to-light-brown powder, produced from citrus fruits for use as an edible gelling agent, especially in jams and jellies, dessert fillings, medications, and sweets; as a food stabiliser in fruit juices and milk drinks; and as a source of dietary fiber. — Wikipedia

Clinical trial activity

26 trials · 21 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
10
Phase 3
7
Phase 4
2

Earliest trial started Aug 1, 2002 (NCT00184522)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • aflurax
  • aflurax
  • calcium pectinate
  • idoflux
  • methoxylpectin
  • methoxypectin
  • methoxy pectin
  • pectin
  • pectin
  • pectin
  • pectin
  • pectin
  • pectinic acid
  • zinc pectinate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07093346N/AJun 10, 2025University of Nottingham
NCT06955975N/AFeb 10, 2025University of Nottingham
NCT06531993Phase 2Aug 31, 2024Assiut University, Istanbul University
NCT06758570N/AOct 5, 2022University of Nottingham
NCT05354245N/ASep 30, 2022Maastricht University
NCT06580132N/ASep 9, 2021University of Nottingham
NCT04381871Phase 2/Phase 3 (Phase 3)Jun 1, 2020Al-Neelain University, University of Khartoum
NCT04215380Phase 2/Phase 3 (Phase 3)Jan 5, 2020Al-Neelain University
NCT04224168N/AJan 1, 2020University of Tennessee
NCT04191213Phase 2/Phase 3 (Phase 3)Dec 15, 2019Al-Neelain University, University of Khartoum
NCT04114513N/ANov 25, 2019Atlas Biomed
NCT02800629Phase 3Jul 1, 2016Harvard University
NCT02844426Phase 2Sep 1, 2015Jinlin University
NCT02838849Phase 1/Phase 2 (Phase 2)Aug 1, 2015Universidade de Passo Fundo
NCT02376270Phase 4Mar 1, 2015Maastricht University
NCT02291354Phase 2Mar 1, 2015Jinlin University
NCT02379624Phase 1/Phase 2 (Phase 2)Aug 1, 2014Nanjing University
NCT02164877Phase 2Jun 1, 2014Jinlin University, People's Liberation Army of China
NCT02016469N/ADec 1, 2013Jinlin University
NCT01960946N/AOct 1, 2013Harvard University, National Heart, Lung, and Blood Institute (NHLBI)
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (21)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Jinlin UniversityAcademic/Hospital4422013
University of NottinghamAcademic/Hospital4412021
Al-Neelain UniversityAcademic/Hospital3312019
People's Liberation Army of ChinaGovernment3222009
Harvard UniversityAcademic/Hospital2222013
Maastricht UniversityAcademic/Hospital2222015
University of KhartoumAcademic/Hospital2012019
Wageningen UniversityAcademic/Hospital2212010
Amitabha Medical Clinic and Healing CenterAcademic/Hospital1012013
Assiut UniversityAcademic/Hospital1112024
Atlas BiomedFor profit1112019
EcoNugenicsFor profit1112013
Ferrosan ASFor profit1012002
Istanbul UniversityAcademic/Hospital1012024
Nanjing UniversityAcademic/Hospital1112014
National Heart, Lung, and Blood Institute (NHLBI)Government1012013
Norwegian University of Science and TechnologyAcademic/Hospital1112002
Tel Aviv UniversityAcademic/Hospital1012013
The University of Texas, DallasAcademic/Hospital1012013
Universidade de Passo FundoAcademic/Hospital1112015
21 organizations
Page 1 / 2